Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Roche adjusts Avastin franchise defense plans as PhII successor fails a key study
Roche adjusts Avastin franchise defense plans as PhII successor fails a key study
Roche adjusts Avastin franchise defense plans as PhII successor fails a key study
Submitted by
admin
on October 21, 2016 - 10:01am
Source:
Endpoints
News Tags:
Roche
Avastin
Vanucizumab
Headline:
Roche adjusts Avastin franchise defense plans as PhII successor fails a key study
Do Not Allow Advertisers to Use My Personal information
